INTRODUCTION
Atrial fibrillation is the most common cardiac arrhythmia, with a global health burden of approximately 33.5 million individuals with atrial fibrillation worldwide. 1 The lifetime risk for developing atrial fibrillation is 21% to 23% in women and 17% to 26% in men. [2] [3] [4] In the past 5 decades, age-adjusted atrial fibrillation prevalence globally has increased 5-fold 5 and is expected to double by 2050. 1 Atrial fibrillation-related stroke is devastating, which has been described as an "atrial fibrillation-related stroke tsunami" without proper treatment with oral anticoagulants. 6 The underuse or inappropriate use of oral anticoagulants is common in the population with atrial fibrillation, particularly so in many Asian countries. 7 Even in the new era of non-vitamin K antagonist oral anticoagulants, 5 many patients remain undertreated. 8 Also, 28% of high-risk patients (defined as a CHA2DS2-VASc [Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA, Vascular disease, Age 65-74 years, Sex category] score ≥2) are not anticoagulated, whereas 51% of very lowrisk patients are inappropriately anticoagulated. 9 Nonadherence to atrial fibrillation guidelines is common across all risk strata, ranging from 33% to 68% among the high-risk population. 10 On the other hand, patients' preferences are another important reason for nonadherence to therapy. 11 Thus, efforts to streamline decision-making for stroke prevention in patients with atrial fibrillation and to improve patients' knowledge are important in the era of non-vitamin K antagonist oral anticoagulants. 12 Novel strategies that incorporate eHealth or Mobile Health encompass the use of information and communication technologies in the management of disease, providing innovative solutions to the problem of long-term management after discharge. 13, 14 However, there are limited data on the implementation of Mobile Health technology for the management of patients with atrial fibrillation, particularly in relation to its feasibility, efficacy, and safety.
Our aim was to perform a randomized, controlled trial (mAFA; Clinical Trials Registry Number: ChiCTR-IOR-17010436) of a Mobile Health technology-supported atrial fibrillation management model, integrating clinical decision support tools, guideline-based treatment, and patient involvement. The mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation. Figure 1, available online) .
MATERIALS AND METHODS
Patients' knowledge, quality of life, drug adherence, and anticoagulation satisfaction were evaluated at baseline, 1 month, and 3 months. Usability, feasibility, and acceptability of the mAF App were assessed at 1 month.
Design of mAF App
The mAF App was designed with versions for patients and doctors respectively. The mAF App incorporates details such
CLINICAL SIGNIFICANCE
• Mobile Health technology is increasingly proposed for cardiovascular disease management.
• The feasibility, efficacy, and safety of Mobile Health technology for the management of patients with atrial fibrillation are unknown.
• The pilot mAFA Trial demonstrated that an approach integrating clinical decision support, education, and patientinvolvement strategies using the mAF App would translate to significantly improved knowledge, drug adherence, anticoagulant satisfaction, and quality of life.
as the Personal Health Record, stroke and bleeding risk assessment (CHA2DS2-VASc and HAS-BLED scores, respectively), and a clinical score to aid warfarin control prediction (SAMe-TT2R2), patient educational programs, patient involvement self-care items, and structured follow-up components. Figure 2 , available online).
Personal
Patients with a low stroke risk (CHA2DS2-VASc score 0 in men, 1 in women) were recommended no antithrombotic treatment. Patients at moderate stroke risk (1 stroke risk factor) were suggested to consider oral anticoagulants balancing against bleeding risk, and those at high stroke risk (CHA2DS2-VASc ≥2) were recommended oral anticoagulants. Patients with HAS-BLED ≥3 were flagged for followup, and modifiable bleeding risk factors were proactively addressed. Because non-vitamin K antagonist oral anticoagulants are "self-pay" drugs and not reimbursed in China, if the patients had a SAMe-TT2R2 score 0 to 2, they were considered to receive warfarin treatment. If the SAMe-TT2R2 score was >2, the patients would have additional education/ counseling about warfarin and more regular review/ international normalized ratio checks, or to use a nonvitamin K antagonist oral anticoagulant.
Patient's Educational Program. There were 8 components of the patient's educational program, with additional patient self-support items. Patients followed the educational program on their mobile device to improve their knowledge of atrial fibrillation and learn how to manage themselves at home (Supplementary Figure 3 , available online). Patients' knowledge and understanding were assessed at baseline, 1 month, and 3 months using a 11-item questionnaire regarding atrial fibrillation.
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Patient Involvement with Self-Care. The patients were encouraged to monitor their heart rate and blood pressure, and feedback on their treatment using the mAF App (Supplementary Figure 4 , available online). Their quality of life was assessed using the Euro EQ-5D-Y at baseline, 1 month, and 3 months.
Structured Follow-Up. Structured follow-up was planned at 1, 3, 6, 9, and 12 months after consultation/discharge, and included assessment of drug therapy, thrombotic events, bleeding events, quality of life, oral anticoagulant satisfaction, and mAF App investigations (Supplementary Figure 5 , available online). A reminder "alert" was sent automatically to patients 1 week before and after the follow-up time-point by the mAF App.
The patients' drug adherence was assessed at baseline, 1 month, and 3 months with the Pharmacy Quality Alliance adherence measure, with a 3-item Adherence Estimator. 16 The Anti-Clot Treatment Scale was adapted to evaluate the satisfaction of patients with oral anticoagulants in this Chinese population with atrial fibrillation (Supplementary Table 1 , available online).
Data Management, Quality Control, Data Security, and Ethics
Users had a user-sensitive password for access to their mAF App. Personal Health Records were stored as structured data on a cloud platform. For example, the medical records and laboratory tests could be uploaded to mAF App as image files, and then the image files were transferred into structured data with optical character recognition technology. Two persons independently double checked the structured data and the source documentation (ie, the image files of laboratory tests and medical records) for consistency and accuracy to achieve good-quality control of data management.
Health Insurance Portability and Accountability Act requirements were adopted to confirm data security during data transfer and data storage, in terms of the Administrative Procedures, Physical Safeguards, Technical Security Services, and Technical Security Mechanisms. Data input into analysis was performed by 2 individuals, who were blinded for the intervention groups. Data were double checked independently by a third investigator. Patient records and information were anonymized and de-identified before analysis.
The Medical Ethics Committee of PLA General Hospital and the China Food and Drug Administration (Registry Number: XZF20120145) approved the present study protocol (Approval Number: S2016-086-01). The present study was registered in the Chinese Clinical Trial Registry, International Clinical Trials Registry Platform of the World Health Organization (ChiCTR-IOR-17010436).
Statistical Analysis
Continuous variables were tested for normality by the Kolmogorov-Smirnov test. Data with a normal distribution are presented as a mean (standard deviation) and analyzed using the t test. Data with a non-normal distribution are presented as median (interquartile range). The comparison of discrete variables was performed using the chi-square test.
The usability, feasibility, and acceptability of the mAF App were investigated at 1 month, and the satisfaction rate was calculated. Data on patients' knowledge, quality of life scores, antithrombotic drugs, and other drugs at the 3 time-points (baseline, 1 month, and 3 months) were presented graphically to illustrate the change in these variables over time between the mAF App and usual care groups. Trends of improvement of patients' knowledge at baseline, 1 month, and 3 months were analyzed with Cochran's and Mantel-Haenszel statistics.
Patients' adherence to drug therapy was calculated using the 3-item Adherence Estimator scores, comparing patients with usual care and mAF App, and was analyzed with the Mann-Whitney U test.
Comparative analysis of Anti-Coagulation Satisfaction and Quality of Life questionnaire scores (EuroQol, EQ-5D-Y) between patients with usual care and the mAF App was performed using t tests, and the chi-square test was used for comparisons of improvement of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression at baseline, 1 month, and 3 months.
A sample size of 112 patients (56 in each group) allows for a 20% attrition rate in the completion of the questionnaires and would have at least 80% power to detect an 18.5% increase in knowledge about the condition between baseline and follow-up. 17 A beta = 0.20 and alpha = 0.05 were assumed.
A P value <.05 was considered statistically significant. The 95% confidence intervals were calculated on the basis of Poisson distribution. Statistical analysis was performed using IBM SPSS Statistics version 21.0 (SPSS, Inc, Chicago, Ill).
RESULTS
In a cluster randomization design, 113 patients were randomized to mAF App intervention (mean age, 67.4 years; 57.5% were male) with a mean follow-up of 69 days, whereas 96 patients were randomized to usual care (mean age, 70.9 years; 55.2% were male) with a mean follow-up of 95 days. Of the original cohort, 113 patients with the mAF App had a 1-month follow-up and 71 patients finished the 3-month follow-up; 96 patients with usual care had 1-month and 3-month follow-up visits.
Hypertension, coronary artery disease, diabetes, and heart failure were the most common comorbidities in both groups ( Table 1 ). The patients with the mAF App had more prior atrial fibrillation ablation therapy (P = .036).
Usability, Feasibility, Acceptability of the mAF App
More than 90% of patients agreed that the mAF App was easy, user-friendly, and helpful, and they had good feedback with the doctors on the mAF App (Supplementary Figure 6 , available online).
Patients' Knowledge on Atrial Fibrillation
Patients' knowledge was improved greatly in those with the mAF App over time (all P < .05), whereas this was not observed in the patients with usual care (Figure 1) .
Quality of Life Improvement in Patients with the mAF App
Quality of life scores were significantly increased in the mAF App arm compared with usual care at baseline and 1 and 3 months (all P < .05) (Figure 2) . Self-care improved significantly over time with the mAF App, but not in usual care (all P < .05). Anxiety and depression also tended to be ameliorated for patients using the mAF App compared with usual care over time (all P < .05) ( Table 2) .
Drug Adherence to Therapy
Compared with patients with usual care, drug adherence was significantly better with the mAF App at 1 month and 3 months (all P < .05) ( Table 3) . Patients with the mAF App were more likely to receive non-vitamin K antagonist oral anticoagulants, ranging from 40.7% to 44.2%, compared with those with usual care (P < .001). There was a slight increase in nonvitamin K antagonist oral anticoagulant use (3.52%) over time in patients using the mAF App (Figure 3) . Secondary prevention of comorbidities for atrial fibrillation was improved in patients with the mAF App compared with patients with usual care (Supplementary Figure 7 , available online).
Anticoagulation Satisfaction
Patients with usual care expressed more anticoagulant "burden," whereas patients with the mAF App reported more anticoagulant "benefit" (all P < .05) ( Table 4) .
DISCUSSION
To our knowledge, the mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation, demonstrating that the mAF App, integrating clinical decision support, education, and patient-involvement strategies, significantly improved knowledge, drug adherence, quality of life, and anticoagulation satisfaction.
Clinical decision support provided by the mAF App streamlined guideline-based decision-making for stroke prevention in patients with atrial fibrillation and was easily handled by doctors and understood by patients. The clinical decision support tools in the mAF App automatically assessed stroke and bleeding risk, and stratified the patients with high-risk stroke/thromboembolism to anticoagulant treatment, while balancing the bleeding risk. Bleeding risk factors were labeled and could be reviewed by doctors and patients. Personalized choice of oral anticoagulants would be advised on the basis of the SAMe-TT2R2 score, resulting in rational decisionmaking on anticoagulant management options.
Suboptimal thromboprophylaxis in patients with atrial fibrillation is highly prevalent, contributed to by an inappropriate evaluation of the risks versus benefits of oral anticoagulants, despite various guidelines on atrial fibrillation management. 18, 19 Indeed, guideline-adherent antithrombotic management is associated with significantly better outcomes. 20 One barrier to adherence to guideline-optimized therapy could be the challenges of a "real-world" busy clinical practice, and the clinical decision-making tool in the mAF App could make the process of guideline implementation easier.
To help access to guidelines for the clinician, a pocket guideline App for European guidelines has been developed. The CATCH-ME treatment manager is integrated into the atrial fibrillation section, but has yet to be prospectively tested or evaluated. 21 Another option is the Atrial Fibrillation Decision Support Tool, which is a patient-specific decision analytic model composed of a 29-state Markov simulation, using information from the Electronic Health Record to integrate patient-specific risk factors for stroke and hemorrhage in its calculations. 22 However, the intervention with the Atrial Fibrillation Decision Support Tool did not result in significant improvements in discordant antithrombotic therapy in a population with atrial fibrillation. 23 Other Apps have been developed to provide stroke and bleeding risk calculations; for example, the Computerised Antithrombotic Risk Assessment Tool Version 2 could calculate the CHADS2 (Congestive heart failure, Hypertension, Age over 75 years, Diabetes Mellitus, Stroke), CHA2DS2-VASc, HAS-BLED, and HEMORR2-HAGES (Hepatic or renal disease, Ethanol abuse, Malignancy, Older age, Reduced platelet count or function, Rebleeding risk, Hypertension, Anemia, Genetic factors, Excessive fall risk, Stroke) scores. 24 Another clinical decision support tool, which could calculate the CHA2DS2-VASc score and alter the clinician prescription of oral anticoagulants therapy, is being studied. 25 However, these Apps/tools are focused on doctors and not the follow-up and day-to-day management of patients with atrial fibrillation.
The mAF App not only calculates the clinical risk scores but also automatically makes a follow-up plan, permitting the patient's self-monitoring and timely feedback. We also show that the mAF App-based self-monitoring and feedback enhanced compliance and adherence to drug therapy and Clinical follow-up ensures effective and safe anticoagulant therapy in patients with atrial fibrillation. A systematic review of drug adherence, thromboembolism, bleeding events, any adverse effects, renal or hepatic function, and so forth, is recommended for non-vitamin K antagonist oral anticoagulants, 26, 27 although anticoagulation tests are not needed. In one study, approximately two thirds of practitioners adhered to recommendations on clinical and blood test (creatinine and hemoglobin) follow-ups. 28 Clinical risk monitoring is important, particularly for bleeding risk management after discharge/prescription of non-vitamin K antagonist oral anticoagulants, and the mAF App allows a practical tool to monitor the patient's clinical risk profile in "real time" allowing a dynamic assessment (and reassessment) of patient risks and changes over time. Moreover, the educational programs provided by the mAF App improved atrial fibrillationrelated knowledge and patient's quality of life. Patient anxiety and depression also were attenuated.
Contemporary atrial fibrillation clinical guidelines advocate incorporation of patient preferences for treatment and support, as well as patient engagement in management decisions. 21, 29 Nonetheless, patient beliefs and misconceptions about their treatment and atrial fibrillation could affect their ability and willingness to adhere to treatment recommendations. 29 A prior study mAF App = mobile AF App; SD = standard deviation. *Compared with the patients with usual care, P < .05. The Anti-Clot Treatment Scale was adapted to evaluate the satisfaction of patients with anticoagulant therapy in this Chinese population with atrial fibrillation. The adapted Anti-Clot Treatment Scale included a 15-item questionnaire, comprising 11 burden items and 4 benefit items. For every question, there are 5 item responses: "1, not at all" was calculated as 1 points; "2, a little" was calculated as 2 points; "3, moderately" was calculated as 3 points; "4, quite a bit" was calculated as 4 points; and "5, extremely" was calculated as 5 points.
has confirmed that a bespoke education intervention significantly improved anticoagulation control of warfarin. 30 A higher patient education level has been associated with nonvitamin K antagonist oral anticoagulant selection. 31 The mAF App provides the specific educational components, in terms of warfarin, non-vitamin K antagonist oral anticoagulants, and specific conditions, that may help patients with self-management.
Study Limitations
Some limitations of this study need to be addressed. This was a clustered randomized study, and a selection bias could exist; however, the distribution of comorbidities between the mAF App and the usual care arms were not significantly different. Moreover, the clinician's preference for oral anticoagulants may have contributed to a higher rate of non-vitamin K antagonist oral anticoagulant use in the mAF App group. The educational program could have made the patients more aware and thus be more likely to receive non-vitamin K antagonist oral anticoagulants. Finally, the impact on the clinical outcomes (stroke, death, bleeds) of the mAF App needs to be ascertained in a long-term prospective study with clinical outcome data, which was not the principal objective of the present study.
Despite these limitations, the present study still shows that the clinical decision support, evidence-based clinical followup, and patients' involvement in self-care can help clinical management for the population with atrial fibrillation, highlighting for the first time an effective Mobile Healthsupport management strategy in such patients.
CONCLUSIONS
The pilot mAFA Trial is the first prospective randomized trial of Mobile Health technology in patients with atrial fibrillation, demonstrating that an approach integrating clinical decision support, education, and patient-involvement strategies will translate to significantly improved knowledge, drug adherence, anticoagulant satisfaction, and quality of life. 
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